Current stock research snapshot · 8/22/26 Fresh

FTREFortrea

WATCH

Investment conviction●●○○○2 of 5 · current snapshot

Research target$21Current stock price target

Investment thesis statusINTACTLast reviewed 8/22/26

Market cap1.63BSnapshot value · 8/22/26

Research history

What changed

Aug 28, 2026

Target
$21.42 → $21

Aug 27, 2026

Target
$21.41 → $21.42

Current investment thesis

Full-service CRO, spun from Labcorp. Turnaround story — lower margin, smaller scale than IQV/ICLR/MEDP. Higher risk, higher potential upside.

Current stock catalysts

Turnaround execution under independent management; biotech funding recovery; FSP model adoption; potential M&A target in consolidating CRO market.

Current investment risks

Turnaround execution risk; smaller scale creates competitive disadvantage vs IQV/ICLR; margin pressure; Labcorp spin-off overhang.

Stock social sentiment

Bullish — Barclays raised PT to $18 from $16 (Overweight) noted in late June/early July watchlists [X search Aug 2026]

Snapshot · 8/22/26

Institutional positioning

🟡 Mixed · ins-$4.5M · 13F 16+/8-×0.5 · short↑0.34

Snapshot · 8/22/26